Acumen Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
ABOS$0.23-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $66,886 | $130,101 |
| Marketable securities, short-term | 176,636 | 47,504 |
| Prepaid expenses and other current assets | 3,093 | 2,724 |
| Total current assets | 246,615 | 180,329 |
| Marketable securities, long-term | 62,553 | 15,837 |
| Restricted cash | 233 | — |
| Property and equipment, net | 122 | 165 |
| Right-of-use asset | 381 | 105 |
| Other assets | 221 | 151 |
| Total assets | $310,125 | $196,587 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $1,379 | $1,640 |
| Accrued clinical trial expenses | 4,387 | 2,717 |
| Accrued expenses and other current liabilities | 6,339 | 3,350 |
| Finance lease liability, short-term | 756 | — |
| Operating lease liability, short-term | 110 | 105 |
| Total current liabilities | 12,971 | 7,812 |
| Operating lease liability, long-term | 284 | — |
| Debt, long-term | 29,897 | — |
| Total liabilities | 43,152 | 7,812 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and 2022; 57,910,461 and 41,025,062 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 6 | 4 |
| Additional paid-in capital | 489,453 | 359,949 |
| Accumulated deficit | (222,798) | (170,427) |
| Accumulated other comprehensive income (loss) | 312 | (751) |
| Total stockholders’ equity | 266,973 | 188,775 |
| Total liabilities and stockholders’ equity | $310,125 | $196,587 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.